Colorectal cancer - New advances in immunotherapy

被引：13

作者：

Cubas, Rafael

Li, Min

Chen, Changyi

Yao, Qizhi

机构：

[1] Baylor Coll Med, Michael E DeBakey Dept Surg, Houston, TX 77030 USA

[2] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA

[3] Baylor Coll Med, Mol Surg Res Ctr, Houston, TX 77030 USA

来源：

CANCER BIOLOGY & THERAPY | 2007年 / 6卷 / 01期

关键词：

colorectal cancer; passive immunotherapy; active immunotherapy; antibodies; vaccines;

D O I：

10.4161/cbt.6.1.3672

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Colorectal cancer remains the second leading cause of cancer-related mortality in the United States. Although surgical resection is still the primary treatment for colorectal cancer, in recent years, there has been a remarkable progress in the development of new therapies to treat colorectal cancer. Response rates have increased substantially and new immunotherapeutic approaches are shedding new light in the battle against the disease. This review will focus on the current immunotherapeutic approaches being developed and will discuss clinical data for some of these new treatments.

引用

收藏

页码：11 / 17

页数：7

相关论文

共 68 条

[1] EpCAM - A new therapeutic target for an old cancer antigen [J].

Armstrong, A ;

Eck, SL .

CANCER BIOLOGY & THERAPY, 2003, 2 (04) :320-325

[2] Making use of the primary tumour [J].

Baars, A ;

Buter, J ;

Pinedo, HM .

BIOESSAYS, 2003, 25 (01) :79-86

[3] Dendritic cell-based cancer immunotherapy: Potential for treatment of colorectal cancer? [J].

Chen, WX ;

Rains, N ;

Young, D ;

Stubbs, RS .

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2000, 15 (07) :698-705

[4] Phase III trial of 5-fluorouracil and leucovorin plus either 3H1 anti-idiotype monoclonal antibody or placebo in patients with advanced colorectal cancer [J].

Chong, G ;

Bhatnagar, A ;

Cunningham, D ;

Cosgriff, TM ;

Harper, PG ;

Steward, W ;

Bridgewater, J ;

Moore, M ;

Cassidy, J ;

Coleman, R ;

Coxon, F ;

Redfern, CH ;

Jones, JJ ;

Hawkins, R ;

Northfelt, D ;

Sreedharan, S ;

Valone, F ;

Carmichael, J .

ANNALS OF ONCOLOGY, 2006, 17 (03) :437-442

[5] Antibody-based therapies for colorectal cancer [J].

Chung, KY ;

Saltz, LB .

ONCOLOGIST, 2005, 10 (09) :701-709

[6] Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry [J].

Chung, KY ;

Shia, J ;

Kemeny, NE ;

Shah, M ;

Schwartz, GK ;

Tse, A ;

Hamilton, A ;

Pan, D ;

Schrag, D ;

Schwartz, L ;

Klimstra, DS ;

Fridman, D ;

Kelsen, DP ;

Saltz, LB .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (09) :1803-1810

[7] Chemo-immunotherapy of colorectal carcinoma: preclinical rationale and clinical experience [J].

Correale, P ;

Cusi, MG ;

Micheli, L ;

Nencini, C ;

del Vecchio, MT ;

Torino, F ;

Aquino, A ;

Bonmassar, E ;

Francini, G ;

Giorgi, G .

INVESTIGATIONAL NEW DRUGS, 2006, 24 (02) :99-110

[8] In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen [J].

Correale, P ;

Walmsley, K ;

Nieroda, C ;

Zaremba, S ;

Zhu, MZ ;

Schlom, J ;

Tsang, KY .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1997, 89 (04) :293-300

[9] Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer [J].

Cunningham, D ;

Humblet, Y ;

Siena, S ;

Khayat, D ;

Bleiberg, H ;

Santoro, A ;

Bets, D ;

Mueser, M ;

Harstrick, A ;

Verslype, C ;

Chau, I ;

Van Cutsem, E .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (04) :337-345

[10]

CUNNINGHAM D, 2003, P AN M AM SOC CLIN, V22, P1012

← 1 2 3 4 5 6 7 →